Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05506956 · ClinicalTrials.gov registry record · Phase 1
Post-transplant Flotetuzumab for AML
A Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT05506956 is a Phase 1 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 3 participants.
The verdict
NCT05506956, a Phase 1 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine if the study drug, flotetuzumab, is safe and tolerable when given to participants with acute myeloid leukemia (AML) that has relapsed after transplant.
Interventions
- DRUG Flotetuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2022-10-20 |
| Est. Completion | 2024-06-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05506956
The ClinicalTrials.gov registry entry for NCT05506956 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Flotetuzumab is the first listed.
NCT05506956 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05506956 about?
NCT05506956 is a clinical study titled "Post-transplant Flotetuzumab for AML". The purpose of this research study is to determine if the study drug, flotetuzumab, is safe and tolerable when given to participants with acute myeloid leukemia (AML) that has relapsed after transplant.
What is the current status of trial NCT05506956?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2022-10-20. Estimated completion is 2024-06-18.
What interventions are being tested in trial NCT05506956?
The interventions under investigation include: Flotetuzumab (DRUG).
Who is sponsoring clinical trial NCT05506956?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.